Why the FDA Probably Won't Approve an Expanded Indication for Amarin Corporation PLC's Vascepa

Published: Oct 16, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

On Wednesday an FDA advisory panel will consider an expanded indication for Amarin Pharmaceuticals’ Vascepa, an EPA fish oil product currently indicated only for people with severe hypertriglyceridemia (>500 mg/dl). The new indication would greatly expand the patient population eligible to receive Vascepa, from the relatively few people with severe hypertriglyceridemia to the many millions with elevated triglycerides (>200 mg/dl) and existing CV disease or at high risk for CV disease. The NDA for this indication is based on the ANCHOR trial, which showed that Vascepa lowered triglycerides in the target patient population.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news